chrX-100667294-G-A
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 0P and 7B. BP4_ModerateBP6BS2
The NM_014467.3(SRPX2):c.982G>A(p.Val328Ile) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000612 in 1,209,559 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 24 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_014467.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SRPX2 | NM_014467.3 | c.982G>A | p.Val328Ile | missense_variant | 9/11 | ENST00000373004.5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SRPX2 | ENST00000373004.5 | c.982G>A | p.Val328Ile | missense_variant | 9/11 | 1 | NM_014467.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000269 AC: 3AN: 111690Hom.: 0 Cov.: 24 AF XY: 0.0000295 AC XY: 1AN XY: 33868
GnomAD3 exomes AF: 0.000289 AC: 53AN: 183456Hom.: 0 AF XY: 0.000236 AC XY: 16AN XY: 67892
GnomAD4 exome AF: 0.0000647 AC: 71AN: 1097869Hom.: 0 Cov.: 31 AF XY: 0.0000633 AC XY: 23AN XY: 363253
GnomAD4 genome AF: 0.0000269 AC: 3AN: 111690Hom.: 0 Cov.: 24 AF XY: 0.0000295 AC XY: 1AN XY: 33868
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 26, 2022 | The c.982G>A (p.V328I) alteration is located in exon 9 (coding exon 8) of the SRPX2 gene. This alteration results from a G to A substitution at nucleotide position 982, causing the valine (V) at amino acid position 328 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Rolandic epilepsy, intellectual disability, and speech dyspraxia, X-linked Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 01, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at